Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05854992 · ClinicalTrials.gov registry record
Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 68,419
- Enrollment target
NCT05854992: Completed study, sponsored by Mayo Clinic.
NCT05854992 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 68,419 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05854992 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 68,419 participants
- Enrollment target
Study Summary
Researchers are evaluating the safety of triptan treatment of migraine in individuals with elevated cardiovascular risk and in pregnant women.
Primary Outcome
Treatments of Migraine With Triptans in Individuals With Elevated Cardiovascular Risk: number of subjects to experience major adverse cardiovascular events (MACE) which consists of all-cause death, nonfatal myocardial infarction, nonfatal stroke, heart failure, transient cerebral ischemia, or revascularization
Interventions
- DRUG Acute migraine treatment with any prescribed triptans
- DRUG Standard of care management of acute migraine without triptans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68,419 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2024-11-01 |
What the finished NCT05854992 record still lists
NCT05854992 is an observational study that tracks outcomes without assigning an intervention. Its 68,419 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Acute migraine treatment with any prescribed triptans is the first listed.
NCT05854992 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05854992 about?
NCT05854992 is a clinical study titled "Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women". Researchers are evaluating the safety of triptan treatment of migraine in individuals with elevated cardiovascular risk and in pregnant women.
What is the current status of trial NCT05854992?
This trial is currently completed. The enrollment target is 68,419 participants. The study started on 2022-07-05. Estimated completion is 2024-11-01.
What interventions are being tested in trial NCT05854992?
The interventions under investigation include: Acute migraine treatment with any prescribed triptans (DRUG), Standard of care management of acute migraine without triptans (DRUG).
Who is sponsoring clinical trial NCT05854992?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00009633 · 68,000 participants
Follow-up Visit of High Risk Infants
- NCT06903897 · 68,000 participants · NA
Social Needs Screening and Chronic Diseases Study (WE CARE)
- NCT04473833 · 65,000 participants · NA
Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer
- NCT05128006 · 63,200 participants
Direct-to-patient Teledermatology and Computer-assisted Diagnosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI